Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Bassetti, M., Echols, R., Matsunaga, Y., … Nagata, T. D. - 2021 - The Lancet Infectious Diseases, 21(2), 226–240